Abstract:Abstract To date, dysregulation of more than 450 RNA-binding proteins (RBPs) across a multitude of cancers has been implicated in tumorigenesis and chemoresistance. In fact, emerging evidence suggests RBPs are principal modulators of every hallmark of cancer progression. Functionally, RBPs are believed to modulate the stability, localization, and translation of transcripts encoding for virtually all known oncogenes and tumor suppressor genes. Consequently, aberrant expression of RBPs may contribute to the malignant transformation of cancer cells through enhancing the expression of oncogenes or decreasing the expression of tumors suppressor genes, such as TP53. As a potent transcription factor, TP53 is a leading regulator of numerous signaling pathways involved in tumor suppression. While mutation or deletion of TP53 contributes to tumorigenesis in more than half of all human cancers, suppression of wild-type TP53 expression also drives tumorigenesis. Thus far, multiple RBPs have been implicated in the repression of wild-type TP53, such as RNA-binding motif protein 38 (RBM38). Specifically, RBM38 interacts with eukaryotic translation initiation factor 4E (EIF4E) on the TP53 transcript, preventing EIF4E from binding to TP53 m7G cap, thus inhibiting TP53 translation. We previously demonstrated that Pep8, an 8 amino acid peptide derived from RBM38, disrupts the RBM38-EIF4E complex enhancing TP53 expression. Moreover, Pep8 alone or in combination with doxorubicin, significantly decreased tumor xenograft growth. As activation of wild-type TP53 by targeting non-genetic mechanisms that inhibit TP53 expression is a promising therapeutic tactic for malignancies that carry wild-type TP53, we are developing more efficacious Pep8 derivatives as a novel therapeutic approach for cancers that express wild-type TP53. Citation Format: Chris August Lucchesi, Jin Zhang, Xinbin Chen. Targeting the RBM38-EIF4E complex to increase wild-type p53 as a novel cancer therapeutic strategy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1037.

Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90 Secretion

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

Mutant P53 Drives Pancreatic Cancer Metastasis Through Cell-Autonomous PDGF Receptor Β Signaling

TP53 Mutations Upregulate RCP Expression Via Sp1/3 to Drive Lung Cancer Progression

Mutant p53 Exploits Enhancers to Elevate Immunosuppressive Chemokine Expression and Impair Immune Checkpoint Inhibitors in Pancreatic Cancer

Mutant p53 suppresses innate immune signaling to promote tumorigenesis

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Regulated secretion of mutant p53 negatively affects T lymphocytes in the tumor microenvironment

Mutant P53 in Cancer: Accumulation, Gain-of-Function, and Therapy.

Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins

Wild-Type P53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation.

Targeting mutant p53 stabilization for cancer therapy

Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Mutant p53 in Cancer Progression and Targeted Therapies

Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis